Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II BEZ235 monotherapy in advanced or metastatic transitional cell carcinoma
2012-004123-20Phase 2Terminated
- Sponsor
- King Albert II Cancer Institute
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dactolisib in transitional cell carcinoma (TCC), sponsored by King Albert II Cancer Institute. Primary endpoint: Progression-free survival rate at 16 weeks. Started Oct 2012; status: terminated.
02
Drugs
dactolisib
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2012-004123-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004123-20.